Indraprastha Medical Corporation Limited (INDRAMEDCO) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Indraprastha Medical Corporation Limited ₹334, price ₹339, upside -1.4%, quality 68 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Indraprastha Medical Corporation Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.
How to read this chart
60‑month range ₹48.65 – ₹622.80 · fair‑value band ₹206.65 – ₹447.05 · the ₹338.60 price screens above the ₹334.02 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 1, 2026.
Follow Indraprastha Medical Corporation in your weekly email
Every Wednesday you see whether Indraprastha Medical Corporation is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Indraprastha Medical Corporation Limited provides hospital services in India.
Show more
Indraprastha Medical Corporation Limited provides hospital services in India. The company offers services primarily in the areas of sugar, genomic medicine, elder care, anesthesiology, bariatric and metabolic surgery, bone marrow transplant, dental and cosmetic clinic, dermatology, dietetics and clinical nutrition, vascular and endovascular surgery, endocrinology, ENT, fetal medicine, general and laparoscopic surgery, gynecology and obstetrics, hyperbaric oxygen therapy, IVF, neonatology, nephrology, nuclear medicine, ophthalmology, pediatric sciences, urology, and plastic surgery, as well as pediatric urology and surgery, physiotherapy and rehabilitation, psychiatry and clinical psychology, radiology and radio diagnosis, respiratory, rheumatology, spine surgery, urology and andrology, cardiology, oncology, emergency, gastroenterology, neuroscience, critical care, orthopedics, robotic surgery, and organ transplant, as well as laboratory services, interventional medicine, preventive medicine, and sleep medicine. Indraprastha Medical Corporation Limited was founded in 1983 and is based in New Delhi, India.
Stock analysis
Indraprastha Medical Corporation Limited (INDRAMEDCO) currently trades at ₹338.60, while our model-based Fair Value estimate is ₹334.02, so the stock looks roughly fairly valued today (gap 1.4%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹351.39 per share, and 14 of the 26 models we run sit above the ₹338.60 price.
Bear case: the Asset-Based group reads lowest at ₹54.11, and 12 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹206.65 (bear) to ₹447.05 (bull), the price of ₹338.60 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Indraprastha Medical Corporation Limited reported revenue of ₹14.8B in FY2026 versus ₹8.9B in FY2022, a compound +13.7%/yr. Reported net income was ₹1.8B in FY2026, compounding +33.0%/yr from FY2022.
Key figures
Market cap ₹31.0B (≈ $322M) · P/E ratio 16.5 · P/S ratio 2.04 · EPS (TTM) ₹20.51 · Dividend yield 1.2% · Net margin 12.4% · Return on equity 27.5% · Return on assets (EBIT) 21.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 46% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −1%, INDRAMEDCO screens richer than that median.
Fair Value models
Bear ₹206.65Fair Value ₹334.02Bull ₹447.05
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹8.37 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+9.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.3%
Start year 2021 (pandemic). Over 10 years: +7.3% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.4%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+34.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+33.3%
Dividend (yield on the price)1.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.33.3% vs 20.6%, picking up
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.1% → 15%
Start year 2021 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+17.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +12.8% a year for the price.
Compare Indraprastha Medical Corporation Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 244 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score68 · Top 25%
Fair Value upside−1.4% · Below median
Profitability
Return on equity (TTM)27.5% · Top 25%
Return on assets15.2% · Top 25%
Net margin (TTM)12.3% · Top 25%
Operating margin (TTM)16.8% · Top 25%
Growth and dividend
Revenue growth11.3% · Above median
Dividend yield (TTM)1.2% · Below median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Indraprastha Medical Corporation Limited Fair Value". https://www.fairvalue-calculator.com/stock/INDRAMEDCO
Frequently asked questions
Is Indraprastha Medical Corporation Limited (INDRAMEDCO) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of ₹334.02 versus a price of ₹338.60, about −1% upside (fairly valued).
What is the fair value of INDRAMEDCO?
Our model-based fair value for Indraprastha Medical Corporation Limited is ₹334.02 (as of Oct 1, 2026), built from audited fundamentals. The current price: ₹338.60.
What is the quality score of INDRAMEDCO?
Indraprastha Medical Corporation Limited has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Indraprastha Medical Corporation Limited (INDRAMEDCO)?
Our model-based price target is the fair value of ₹334.02 (as of Oct 1, 2026) from 26 valuation models. Cautious scenario ₹206.65, optimistic scenario ₹447.05. It is a calculation from audited fundamentals, not an analyst target.
What is the Indraprastha Medical Corporation Limited stock forecast for 2026?
Our models put fair value at ₹334.02, about −1% upside versus a price of ₹338.60 (fairly valued). Cautious scenario ₹206.65, optimistic scenario ₹447.05. The calculation is refreshed regularly with new filings.
What is the revenue of Indraprastha Medical Corporation Limited (INDRAMEDCO)?
Indraprastha Medical Corporation Limited reported trailing-twelve-month revenue of about ₹15.2B (latest available figure, as of Oct 1, 2026).
Does Indraprastha Medical Corporation Limited pay a dividend?
Indraprastha Medical Corporation Limited currently shows a dividend yield of about 1.18% relative to its recent price (as of Oct 1, 2026).
What growth is priced into Indraprastha Medical Corporation Limited (INDRAMEDCO)?
For today's price to be fair in a discounted-cash-flow model, Indraprastha Medical Corporation Limited would have to grow free cash flow by +17.5 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +19.3 % per year. As of Oct 1, 2026.
What discount rate (WACC) does the fair value of INDRAMEDCO use?
Our models discount Indraprastha Medical Corporation Limited at 12.4 %: a base by market capitalisation (small), damped by beta 0.43, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Indraprastha Medical Corporation Limited that is +17.5 % per year a year over ten years, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has Indraprastha Medical Corporation Limited (INDRAMEDCO) delivered so far?
Over the past 5 years revenue at Indraprastha Medical Corporation Limited grew +19.3 % a year. The price currently implies +17.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Indraprastha Medical Corporation Limited (INDRAMEDCO) growing?
The median revenue growth in the sector is +4.6 % a year. That is the yardstick for the growth priced into Indraprastha Medical Corporation Limited (+17.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Indraprastha Medical Corporation Limited (INDRAMEDCO)?
The free-cash-flow yield on the price is 4.18 %: that much free cash flow Indraprastha Medical Corporation Limited produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Indraprastha Medical Corporation Limited (INDRAMEDCO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Indraprastha Medical Corporation Limited it is ₹334.02 per share (as of Oct 1, 2026), against a price of ₹338.60. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Indraprastha Medical Corporation Limited stock overvalued or undervalued in 2026?
As of Oct 1, 2026, INDRAMEDCO trades above its calculated fair value: price ₹338.60, fair value ₹334.02, a gap of about −1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of INDRAMEDCO?
No. The price is what the market pays today (₹338.60); the fair value is what the company's own numbers justify (₹334.02). For Indraprastha Medical Corporation Limited the two are ₹4.58 per share apart. That gap is exactly why we show both numbers side by side.
How much is Indraprastha Medical Corporation Limited worth?
The market values Indraprastha Medical Corporation Limited at about ₹31.0B (market capitalisation, as of Oct 1, 2026). Per share that is ₹338.60; our models calculate a fair value of ₹334.02 per share.
What do the bullish and bearish scenarios say about INDRAMEDCO?
Our models span a range for Indraprastha Medical Corporation Limited: cautious scenario ₹206.65, base ₹334.02, optimistic ₹447.05 per share (as of Oct 1, 2026, price ₹338.60). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of INDRAMEDCO?
Indraprastha Medical Corporation Limited trades at a price-to-earnings ratio of 16.5 (as of Oct 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹334.02 is built from several models across several years. Other multiples: P/B 4.2, P/S 2.0, EV/EBITDA 10.4.
How solid is the balance sheet of Indraprastha Medical Corporation Limited (INDRAMEDCO)?
Balance-sheet figures for Indraprastha Medical Corporation Limited (as of Oct 1, 2026): return on equity 27.5%. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is INDRAMEDCO from its 52-week high?
Indraprastha Medical Corporation Limited trades at ₹338.60, about 46% below its 52-week high of ₹622.80 and at the low of ₹338.60 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹334.02 is for.
Which stocks are comparable to Indraprastha Medical Corporation Limited?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Indraprastha Medical Corporation Limited stock attractive at the current price?
The data as of Oct 1, 2026: price ₹338.60, calculated fair value ₹334.02 (−1%), Quality Score 68/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of INDRAMEDCO calculated?
We run Indraprastha Medical Corporation Limited through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹334.02, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Indraprastha Medical Corporation Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Indraprastha Medical Corporation Limited (INDRAMEDCO)?
The closing price on Oct 1, 2026 was ₹338.60. Our model-based fair value is ₹334.02, about −1% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Indraprastha Medical Corporation Limited right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (₹206.65 to ₹447.05) leaves room in how you read the outcome.
Where does the earnings growth of Indraprastha Medical Corporation Limited (INDRAMEDCO) come from?
Earnings per share at Indraprastha Medical Corporation Limited grew +20.6 % a year from 2015 to 2026. Broken into its drivers: revenue per share +7.4 %, EBIT margin −5.3 %, tax rate +1.6 %, residual (interest, one-offs) +16.7 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Indraprastha Medical Corporation Limited
How large is the market capitalisation of Indraprastha Medical Corporation Limited (INDRAMEDCO)?
The market capitalisation of Indraprastha Medical Corporation Limited is ₹31.0B (≈ $322M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Indraprastha Medical Corporation Limited (INDRAMEDCO)?
The price-to-sales ratio of Indraprastha Medical Corporation Limited is 2.04 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Indraprastha Medical Corporation Limited (INDRAMEDCO)?
Earnings per share at Indraprastha Medical Corporation Limited are ₹20.51 (price ÷ EPS = P/E 16.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Indraprastha Medical Corporation Limited (INDRAMEDCO)?
The dividend yield of Indraprastha Medical Corporation Limited is 1.2% (payout 19.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Indraprastha Medical Corporation Limited (INDRAMEDCO)?
The net margin of Indraprastha Medical Corporation Limited is 12.4% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Indraprastha Medical Corporation Limited (INDRAMEDCO)?
The return on equity (ROE) of Indraprastha Medical Corporation Limited is 27.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Indraprastha Medical Corporation Limited (INDRAMEDCO)?
On an EBIT basis the return on assets of Indraprastha Medical Corporation Limited is 21.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Indraprastha Medical Corporation Limited (INDRAMEDCO)?
The operating margin of Indraprastha Medical Corporation Limited is 16.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Indraprastha Medical Corporation Limited (INDRAMEDCO)?
Revenue at Indraprastha Medical Corporation Limited is growing +11.3% versus a year earlier (3y avg +10.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Indraprastha Medical Corporation Limited (INDRAMEDCO)?
Earnings per share at Indraprastha Medical Corporation Limited are growing +8.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Indraprastha Medical Corporation Limited (INDRAMEDCO) hold?
Indraprastha Medical Corporation Limited holds more cash than debt, ₹2.3B net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Indraprastha Medical Corporation Limited in the live analysis
One click puts Indraprastha Medical Corporation Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
